news

Bristol-Myers Squibb to present new remission data on ORENCIA® (abatacept) and Clazakizumab at The European League Against Rheumatism 2014 Annual Meeting

Posted: 21 May 2014 | | No comments yet

Bristol-Myers Squibb Company announced that 20 abstracts for Orencia® (abatacept), and clazakizumab have been accepted for presentation at the 2014 annual meeting of the European League Against Rheumatism…

Bristol Myers Squibb logo

Bristol-Myers Squibb Company (NYSE:BMY) announced today that 20 abstracts for Orencia® (abatacept), and clazakizumab have been accepted for presentation at the 2014 annual meeting of the European League Against Rheumatism (EULAR), to be held June 11-14 in Paris, France. The extensive data being presented underscores the Company’s commitment to develop innovative treatments for patients suffering from rheumatoid arthritis (RA) and other immune-mediated diseases, including its pioneering T-cell co-stimulation modulator, Orencia, and clazakizumab, an investigational selective IL-6 cytokine inhibitor.

“Leveraging our heritage and expertise in immunoscience, Bristol-Myers Squibb remains focused on changing the course of immune-mediated diseases like RA,” said Michael Giordano, senior vice president, Head of Development, Oncology and Immunoscience, Bristol-Myers Squibb. “The clinical results and real-world data we will present at the EULAR annual meeting reflect our commitment to develop innovative therapies to improve the health of patients suffering from RA.”

The complete list of Bristol-Myers Squibb presentations can be found here. Abstracts can be accessed on the EULAR website at https://b-com.mci-group.com/AbstractList/EULAR2014.aspx.

Related organisations